# A Study to Test Combination Treatments in People With Advanced Renal Cell Carcinoma

> **NCT02996110** · PHASE2 · COMPLETED · sponsor: **Bristol-Myers Squibb** · enrollment: 182 (actual)

## Conditions studied

- Advanced Cancer

## Interventions

- **BIOLOGICAL:** Nivolumab
- **BIOLOGICAL:** Ipilimumab
- **BIOLOGICAL:** Relatlimab
- **DRUG:** BMS-986205
- **DRUG:** BMS-813160

## Key facts

- **NCT ID:** NCT02996110
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-02-02
- **Primary completion:** 2021-11-23
- **Final completion:** 2021-11-23
- **Target enrollment:** 182 (ACTUAL)
- **Last updated:** 2022-12-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02996110

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02996110, "A Study to Test Combination Treatments in People With Advanced Renal Cell Carcinoma". Retrieved via AI Analytics 2026-08-12 from https://api.ai-analytics.org/clinical/NCT02996110. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*